Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Urothelial Cancer 1Squamous Cell Carcinoma of Head and Neck 1Spinocerebellar Degenerations 1Small Cell Lung Carcinoma 1Sarcoma 1Rhabdoid Tumor 1Rectal Neoplasms 1Neoplasms 1Lung Neoplasms 1Esophageal Squamous Cell Carcinoma 1Colorectal Neoplasms 1Chordoma 1Carcinoma, Squamous Cell 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Advanced Solid Malignancies 1Advanced Rare Malignant Solid Neoplasm 1

Interventions

Radiotherapy 11pembrolizumab 10Nivolumab 10Doxorubicin 10Magnetic Resonance Spectroscopy 9Specimen Handling 8Cyclophosphamide 8Biopsy 7X-Rays 6Ipilimumab 6Radiation 5Phantoms, Imaging 5Ifosfamide 5talimogene laherparepvec 4cabozantinib 4Nuclear Medicine Department, Hospital 4Irinotecan 4tazemetostat 3selpercatinib 3pazopanib 3liposomal doxorubicin 3fludarabine 3Temozolomide 3Etoposide 3ulixertinib 2tislelizumab 2tipifarnib 2palbociclib 2larotrectinib 2ivosidenib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Sarcoma × Tiragolumab × Clear all
NCT05286801 2026-05-13

Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
86 enrolled
Sarcoma

Chordoma, Sarcoma, Rhabdoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡